What Is Nipah Virus?

Nipah virus (NiV) is a zoonotic paramyxovirus carried by Pteropus fruit bats (flying foxes), which causes severe encephalitis (brain inflammation) and respiratory illness in humans. With a case fatality rate of 40–75% and no approved vaccine or specific antiviral treatment, Nipah is among the most lethal viruses known to cause disease in people. Outbreaks have occurred in Malaysia (1998–99), Singapore (1999), Bangladesh (almost annually since 2001), and India (Kerala state, multiple times since 2018). WHO includes Nipah on its R&D Blueprint Priority Pathogen list due to its pandemic potential and significant gaps in countermeasures.

Nipah is transmitted through three main routes:

Bat-to-human: Consuming raw date palm sap contaminated by bat urine or saliva (primary route in Bangladesh); eating fruit partially consumed by bats; direct bat contact in roosts
Animal-to-human: Contact with infected pigs and their secretions (Malaysia 1998–99 outbreak)
Human-to-human: Close contact with body fluids of symptomatic patients — documented in Bangladesh and India. Healthcare workers and family caregivers are highest risk. R0 estimated at 0.3–0.5 in community settings, meaning outbreaks are self-limiting but healthcare amplification has occurred.

Incubation: 4–14 days (up to 45 days reported). Rapid progression:

Early (2–3 days): Fever, headache, drowsiness, disorientation, mental confusion
Encephalitic phase: Altered consciousness, seizures, respiratory distress, coma
Death occurs within 1–2 weeks of onset in fatal cases

Even survivors may experience relapsing encephalitis months to years later as the virus can persist in the CNS. Approximately 20% of survivors have persistent neurological deficits.

Despite 25 years of known risk, Nipah's rarity — outbreaks of 5–50 people — makes large clinical trials nearly impossible. The m102.4 monoclonal antibody (developed by Pfizer/Scripps) has been used under compassionate use with some success and is in Phase 2 trials. Moderna's mRNA-1215 Nipah vaccine showed strong Phase 1 immunogenicity in 2024. CEPI (Coalition for Epidemic Preparedness Innovations) has prioritized Nipah vaccine funding. The challenge is proving efficacy when outbreaks are too small for standard trial designs.

How is Nipah different from Ebola?: Both are rare, high-fatality zoonotic diseases. Key differences: Ebola is a Filovirus causing hemorrhagic fever; Nipah is a Paramyxovirus causing encephalitis. Ebola has approved vaccines and treatments for Zaire species; Nipah has neither. Ebola outbreaks tend to be larger (hundreds to thousands of cases); Nipah outbreaks are smaller (5–50 cases) but occur more frequently. Both can spread human-to-human through body fluid contact.
Should travelers to Bangladesh or India worry about Nipah?: Risk for travelers is very low. Outbreaks are localized, seasonal (Bangladesh: January–March, linked to date palm sap season), and rapidly identified by local health authorities. Travelers should: avoid raw date palm sap in Bangladesh and India during outbreak periods; avoid contact with bats in caves or fruit orchards; and monitor WHO travel advisories. If fever and encephalitis develop within 3 weeks of return, mention any possible bat or animal contact to your doctor.
What makes Nipah a pandemic threat?: The combination of: high lethality (40–75% CFR), documented human-to-human transmission, fruit bat reservoir spanning South and Southeast Asia (with related viruses in Africa), no approved countermeasures, and the theoretical possibility of acquiring efficient airborne transmission. A mutation enabling widespread person-to-person spread in a virus with 40–75% lethality would be catastrophic. This worst-case scenario drives Nipah's WHO Priority Pathogen designation.